FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan et al.	
	FILING DATE November 10, 2000	GROUP 1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
NONE							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	No
NONE	.							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

(initials)	A	Koehl *et al.*, "A brighter future for protein structure prediction", *Nature Structure Biology*, 6(2):108-111, 1999
(initials)	B	Sternberg *et al.*, "Progress in protein structure prediction: assessment of CASP3", *Current Opinion in Structural Biology*, 9:368-373, 1999

EXAMINER *(signature)*	DATE CONSIDERED 11/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan et al.	**RECEIVED**
	FILING DATE November 10, 2000	GROUP 1631 JUN 0 7 2002 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	No
	AA	9	5	1	4	7	9	1	06/01/95	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		None

EXAMINER	DATE CONSIDERED 11/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS**

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
APPLICANT Ramnarayan et al.	
FILING DATE November 10, 2000	GROUP 1631

RECEIVED
DEC 07 2001
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
initial	A	5	3	3	1	5	7	3	07/19/94	Balaji et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	No
initial	B	9	5	0	6	2	9	3	03/02/95	PCT				
initial	C	9	5	1	4	0	2	8	05/26/95	PCT				
initial	D	9	8	0	6	0	4	8	02/12/98	PCT				
initial	E	9	8	1	3	7	8	1	04/02/98	PCT				
initial	F	9	8	5	4	6	6	5	12/03/98	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

initial	G	Abdel-Meguid, S.S. et al. "An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis," *Biochemistry* 33(39):11671-11677 (1994)
	H	Blaney, B. "Molecular modelling in the pharmaceutical industry, *Chemistry and Industry. Chemistry and Industry Review* 23(4):791-4 (1990). *not considered no copy provided*
	I	Bohm, G. "New approaches in molecular structure prediction" *Biophysical Chemistry* 59:1-32 (1996) *not considered no copy provided*
initial	J	Thompson, S.K. et al. "Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'-P2' amide bond isoster," *Journal of Medicinal Chemistry* 37(19):3100-3107 (1994).

EXAMINER *J/S. Brusca* | DATE CONSIDERED *11/27/02*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attachment Paper 21

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	**APPLICANT** Ramnarayan et al.	
	FILING DATE November 10, 2000	**GROUP** 1631

TECH CENTER 1600/2900 RECEIVED AUG 14 2002

OIPE AUG 06 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	AA	5	3	1	7	0	9	7	05/31/94	Miller *et al.*	536	24.31	10/07/91
*	AB	5	4	9	5	4	2	3	02/27/96	DeLisi *et al.*	364	496	10/25/93
*	AC	5	5	9	3	9	5	9	01/14/97	Miller *et al.*	514	8	10/14/93
*	AD	5	6	2	4	8	1	7	04/29/97	Miller *et al.*	435	69.1	04/28/94
*	AE	5	6	9	9	2	6	8	12/16/97	Schmidt	364	496	06/07/95
*	AF	5	9	6	8	7	3	7	10/19/99	Ali-Osman *et al.*	435	6	11/12/96
*	AG	5	9	7	8	7	4	0	11/02/99	Armistead *et al.*	702	19	08/09/95
*	AH	6	1	2	8	5	8	2	10/03/00	Wilson *et al.*	702	27	04/30/96

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	No
None														

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	AI	Baker *et al.*, "Protein Structure Prediction and Structural Genomics", Science, 294:93-96 (2001)
*	AJ	Hess *et al.*, "Impact of Pharmacogenomics on the Clinical Laboratory", *Mol. Diagn.*, 4(4):289-98 (1999)
*	AK	Hess *et al.*, "Gene Therapy Monitoring: Clinical Monitoring for Efficacy and Potential Toxicity, *Mol. Diagn.*, 2(2):147-155 (1997)

EXAMINER	DATE CONSIDERED 11/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS**

Attachment # Paper 16

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan et al.	
	FILING DATE November 10, 2000	GROUP 1631

RECEIVED MAR 2 5 2002 TECH CENTER 1600/2900

* References are not included.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	AA	5	7	1	2	1	4	5	01/27/98	Houghton et al.	435	219	09/06/96

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	AB	Ajay et al., Computational Methods to Predict Binding Free Energy in Ligand-Receptor Complexes, Journal of Medicinal Chemistry. 38(26):4953-4967 (1995).
*	AC	Balaji et al., Conformational studies on model peptides with 1-aminocyclopropane 1-carboxylic acid residues, Pept. Res. 7(2):60-71 (1994).
*	AD	Balaji et al., Conformational studies on model peptides with 1-aminocyclobutane 1-carboxylic acid residues, Pept. Res. 8(3):178-86 (1995).
*	AE	Balasubramaniam et al., [D-TRP^{32}]Neuropeptide Y: A Competitive Antagonist of NPY in Rat Hypothalamus, J. Med. Chem. 37(6):811-815 (1994).
*	AF	Böhm, Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs, Journal of Computer-Aided Molecular Design. 12:309-323 (1998).
*	AG	Checa et al., Assessment of Solvation Effects on Calculated Binding Affinity Differences: Trypsin Inhibition by Flavonoids as a Model System for Congeneric Series, J. Med. Chem. 40:4136-4145 (1997).
*	AH	Daniels, Blood group polymorphisms: molecular approach and biological significance, Transfus. Clin. Biol. 4:383-390 (1997).

EXAMINER	DATE CONSIDERED 11/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS**

FORM PTO-1449 (Modified)

MAR 2 1 2002

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

RECEIVED MAR 2 5 2002 TECH CENTER 1600/2900

ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
APPLICANT Ramnarayan et al.	
FILING DATE November 10, 2000	GROUP 1631

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*		AI	Das et al., Crystal Structures of 8-Cl and 9-Cl Complexed with Wild-type HIV-1 RT and 8-Cl TIBO Complexed with the Tyr-81Cys HIV-1 RT Drug-resistant Mutant, J. Mol. Biol. 264:1085-1100 (1996).
*		AJ	Eldridge et al., Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes, Journal of Computer-Aided Molecular Design. 11:425-445 (1997).
*		AK	Fox, S. Pharmacogenomics Thrives in Europe. Genetic Engineering News. June 15, 1999.
*		AL	Leheny et al. Symposium on Resistance Highlights New Trends in AIDS Treatments: Implications for BioChem Pharma and Others, Hambrecht & Quist LLC Institutional Research. pp. 1-7 (1997). not considered no copy provided
*		AM	Manavalan et al., Location of Potential Binding Sites on Deoxy Hemoglobin for the Design of Antigelling Agents, J. Mol. Biol. 223:791-800 (1992).
*		AN	Munson et al., Identification of an extracytoplasmic region of H+, K(+)- ATPase labeled by a K(+)-competitive photoaffinity inhibitor, J. Biol. Chem. 266(28):18976-88 (1991).
*		AO	Novotny et al., Empirical Free Energy Calculations: A Blind Test and Further Improvements to the Method, J. Mol. Biol. 268:401-411 (1997).
*		AP	Press Release, Structural Bioinformatics Inc. and Cyberchemics, Inc. Collaborate to Speed the Generation of Hepatitis C Viral Protease Inhibitors, SBI News. Located at http://strubix.com/press/press5.html, pp. 1-2 (1997).
*		AQ	Press Release, Structural Bioinformatics Inc. Selects IBM RS/6000 SP to Spee Drug Design, SBI News. Located at http://strubix.com/press/press11.html, pp.1-2 (1997).
*		AR	Press Release, SBI Protein Models & Ligand Binding for Novel Viral Enzyme Validated, SBI News. Located at http://strubix.com/press/press32.html, pp. 1-2 (1999).
*		AS	Press Release, Structural Bioinformatics Inc. Generates Antiviral Lead Compound from Gene Sequence to Achieve Milestone in Biochem Pharma Collaboration, SBI News. Located at http://strubix.com/press/press20.html, pp. 1-2 (1998).
*		AT	Press Release, SBI's Protein Structure Directed Combinatorial Chemistry Cuts Time and Cost 100X for Synthesis of New Anti-Inflammatory Drug Lead Molecules (TNF Receptor Antagonists), SBI News. Located at http://strubix.com/press/press19.html, pp. 1-2 (1998).

EXAMINER _____ | DATE CONSIDERED 11/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS**

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
APPLICANT Ramnarayan et al.	
FILING DATE November 10, 2000	GROUP 1631

RECEIVED MAR 2 5 2002 TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*		AU	Press Release, Structural Bioinformatics Inc. Generates Non-Peptide Lead Molecules Active Against the EPO Receptor from Gene Sequence Data, <u>SBI News.</u> Located at http://strubix.com/press/press22.html, pp. 1-2 (1998).
*		AV	Press Release, Structural Bioinformatics Inc. Develops Small-Molecule Antagonists of BCL-2 Gene Product, an Important Apoptosis-Related Protein Target in the Pathology of Human Cancers, <u>SBI News.</u> Located at http://strubix.com/press/press26.html, pp. 1-2 (1999)
*		AW	Radack et al., Intercorrelations and sources of variability in three mutagenicity assays: a population-based study, <u>Mutation Research.</u> 350 (1996); pp. 295-306.
*		AX	Radmer et al., The application of three approximate free energy calculations methods to structure based ligand design: Trypsin and its complex with inhibitors, <u>Journal of Computer-Aided Molecular Design.</u> 12:215-227 (1998).
*		AY	Ramnarayan et al., Antibody humanization predicted by computer graphic analysis, <u>Am. Biotechnol. Lab.</u> 13(9):26,28 (1995).
*		AZ	Ramnarayan et al., Conformational studies on model dipeptides of Gly, L-Ala and their C^{α}-substituted analogs, <u>Int. J. Pept. Protein Res.</u> 45(4):366-76 (1995).
*		BA	Ramnarayan et al., Characterization of a Linear Pentapeptide Containing Two Consecutive β-Turns, <u>Pept. Res.</u> 7(5):270-8 (1994).
*		BB	Regalado, Inventing the pharmacogenomics business, <u>Am. J. Health-Syst. Pharm.</u> 56:40-50 (1999).
*		BC	Rao et al., Conformational Studies on β-Amino Acid-Containing Peptides. I., <u>Pept. Res.</u> 5(6):343-50 (1992).
*		BD	Shafer et al., Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients, <u>Annals of Internal Medicine.</u> 128(11):906-11 (1998).
*		BE	Skaletsky et al., Accessing three-dimensional chemical information in antibody molecules, <u>Am. Biotechnol. Lab.</u> 11(5):10-3 (1993).
*		~~BF~~	~~Shenderovich, et al., "Structural Pharmacogenic Approach to the Evaluation of Drug~~ Resistant Mutations and HIV-1 Protease", <i>Journal of Clinical Ligand Assay,</i> <u>24(2)</u>:140-144 (2001) considered no copy provided

EXAMINER	DATE CONSIDERED 11/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS**

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
APPLICANT Ramnarayan et al.	
FILING DATE November 10, 2000	GROUP 1631

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*		BG	Smith et al., Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action, Protein Engineering. 10(12):1379-83 (1997).
*		BH	Spear, Viewpoint - Pharmacogenomics: Today, Tomorrow, and Beyond, Drug Benefit Trends. 11(2):53-54 (1999).
*		BI	Takamatsu et al., A New Method for Predicting Binding Free Energy Between Receptor and Ligand, Proteins: Structure, Function, and Genetics. 33:62-73 (1998).
*		BJ	Tantillo et al. Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse Transcriptase, J. Mol. Biol. 243:369-387 (1994).
*		BK	Vajda et al. Empirical potentials and functions for protein folding and binding, Theory and Simulation. 7:222-228 (1997).
*		BL	Wang and Kollman, "Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance", PNAS, 98(26):14937-14942 (2001). not considered no copy provided
*		BM	Weng et al., Prediction of protein complexes using empirical free energy functions, Protein Science. 5:614-626 (1996). not considered no copy provided
*		BN	Zhu et al., Identification of two new hydrophobic residues on basic fibroblast growth factor important for fibroblast growth factor receptor binding, Protein Engineering 11(10):937-40 (1998).
*		BO	Zhu et al., Analysis of high-affinity binding determinants in the receptor binding epitope of basic fibroblast growth factor, Protein Eng. 10(4):417-21 (1997).
*		BP	Zhu et al., Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding. Identification by structure-based site-directed mutagenesis, J. Biol. Chem. 270(37):21869-74 (1995).

EXAMINER	DATE CONSIDERED 11/27/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **USE OF COMPUTATIONALLY DERIVED PROTEIN STRUCTURES OF GENETIC POLYMORPHISMS IN PHARMACOGENOMICS FOR DRUG DESIGN AND CLINICAL APPLICATIONS**

| FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24727-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT **RECEIVED**	APPLICANT Ramnarayan *et al.*	
	FILING DATE November 20, 2000	GROUP 1631

AUG 1 5 2001

TECH CENTER 1600/2900 U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	No
✓		0	1	3	5	3	1	6	05/17/01	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER *S. Brown*	DATE CONSIDERED *11/26/02*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan *et al.*	
	FILING DATE November 10, 2000	GROUP 2857 /631

OIPE MAR 0 5 2001 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*		4	2	0	8	4	7	9	06/17/80	Zuk *et al.*	435	7	07/14/77
*		4	2	2	0	4	5	0	09/02/80	Maggio	23	230	04/05/78
*		4	2	3	3	4	0	1	11/11/80	Yoshida *et al.*	435	7	07/14/77
*		4	2	3	3	4	0	2	11/11/80	Maggio *et al.*	435	7	04/05/78
*		4	2	7	7	4	3	7	07/01/81	Maggio	422	61	12/10/79
*		4	3	8	5	1	2	6	05/24/83	Chen *et al.*	436	518	03/19/79
*		4	3	9	7	9	5	6	08/09/83	Maggio	436	34	12/10/81
*		4	7	8	6	4	7	1	11/22/88	Jones *et al.*	422	61	10/21/83
*		4	7	8	9	6	3	1	12/06/88	Maggio	435	7	02/17/84
*		4	8	2	8	9	8	1	05/09/89	Maggio	435	7	08/24/83
*		4	8	5	9	6	1	0	08/22/89	Maggio	436	518	09/12/86
*		5	0	7	9	1	4	2	01/07/92	Coleman *et al.*	435	7.92	01/23/87
*		5	2	1	5	8	9	9	06/01/93	Dattagupta	435	6	08/23/90
*		5	3	3	1	5	7	3	07/19/94	Balaji *et al.*	364	500	12/14/90
*		5	5	7	1	8	2	1	11/05/96	Chan *et al.*	514	312	05/20/94
*		5	5	7	9	2	5	0	11/26/96	Balaji *et al.*	364	496	04/24/95
*		5	6	1	2	8	9	5	03/18/97	Balaji *et al.*	364	496	04/21/95
*		5	7	1	2	1	4	5	01/27/98	Houghton *et al.*	435	219	09/06/96
*		5	8	0	8	9	6	9	09/15/98	Arnaud *et al.*	367	103	12/04/95
*		5	8	3	7	4	6	4	11/17/98	Capon *et al.*	435	6	01/29/97
*		5	8	4	6	7	6	3	12/08/98	Lee *et al.*	435	69.1	05/13/94
*		5	9	1	0	4	7	8	06/08/99	Hlavka *et al.*	514	9	09/20/96

FOREIGN PATENT DOCUMENTS

EXAMINER		DATE CONSIDERED 11/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan *et al.*	
	FILING DATE November 10, 2000	GROUP 2857 /63/

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	No
*	RB	0	0	5	7	3	0	9	09/28/00	PCT				
*	RB	9	7	2	7	3	1	9	07/31/97	PCT				
*	RB	9	7	2	7	4	8	0	07/31/97	PCT				
*	RB	9	9	0	6	5	9	7	02/11/99	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

|		
*		3D-QSAR in Drug Design Kubinyi, H. (ed.) Kluwer Academic Publishers (1993). *not considered, no copy provided*
*	RB	Abagyan *et al.* Biased Probability Monte Carlo Conformational Searches and Electrostatic Calculations for Peptides and Proteins, *J. Mol. Biol.* 235: 983-1002 (1994).
*	RB	Abagyan *et al.* Protein structure prediction by global energy optimization, *Comput. Simul. Biomol. Syst.* 3:363-94 (1997).
*	RB	Ajay *et al.*, Computational Methods to Predict Binding Free Energy in Ligand-Receptor Complexes, Journal of Medicinal Chemistry. 38(26):4953-4967 (1995).
*	RB	Altschul, Gap costs for multiple sequence alignment, J. Theor. Biol., 138:297-309 (1989)
*	RB	Altschul and Lipman, Trees, stars and multiple biological sequence alignment, SIAM J. Appl. Math., 49:197-209 (1989)
*	RB	Altschul, Leaf pairs and tree dissections, SIAM J. Discrete Math., 2:293-299 (1989)
*	RB	Altschul *et al.*, Weights for data related by a tree, J. Molec. Biol., 207:647-653 (1989)
*	RB	Altschul *et al.* Basic Local Alignment Search Tool, *J. Mol. Biol.* 215: 403-10 (1990).
*	RB	Balaji *et al.*, Conformational studies on model peptides with 1-aminocyclopropane 1-carboxylic acid residues, Pept. Res. 7(2):60-71 (1994).
*	RB	Balaji *et al.*, Conformational studies on model peptides with 1-aminocyclobutane 1-carboxylic acid residues, Pept. Res. 8(3):178-86 (1995).
*	RB	Balasubramaniam *et al.*, [D-TRP^{32}]Neuropeptide Y: A Competitive Antagonist of NPY in Rat Hypothalamus, J. Med. Chem. 37(6):811-815 (1994).
*	RB	Balasubramanian, R., New type of representation for mapping chain-folding in protein molecules, *Nature* 266: 856-57 (1977).
*	RB	Bernstein *et al.*, The protein data bank: a computer-based archival file for macromolecule structures, J. Mol. Biol., 112:535-542 (1977)

| EXAMINER	*JtS. Bumara*	DATE CONSIDERED *11/26/02*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT Ramnarayan et al.	
		FILING DATE November 10, 2000	GROUP ~~2857~~ 1631

MAR 0 5 2001

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*		
		~~Biocomputing: Informatics and Genome Projects~~ Smith, D.W., ed. Academic Press, Inc., San Diego (1994). *noT considered no copy provided*
*		Böhm, Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs, <u>Journal of Computer-Aided Molecular Design.</u> 12:309-323 (1998).
*		Bouras et al. Design, Synthesis, and Evaluation of Conformationally Constrained Tongs, New Inhibitors of HIV-1 Protease Dimerization, *42:* 957-62 (1999).
*		Carrillo, H. and D. Lipman., The Multiple Sequence Alignment Problem in Biology, *SIAM J. Appl. Math.* <u>48(5):</u> 1073-82 (1988).
*		Carson and Bugg, Algorithm for ribbon models of proteins, <u>J. Mol. Graphics</u>, 4:121-122 (1986)
*		Carson, Ribbons 2.0, <u>J. Appl. Cryst.</u>, 24:958-961 (1991)
*		Carson, Ribbon models of macromolecules, <u>J. Mol. Graphics</u>, 5:103-106 (1987)
*		Carson, Ribbons, <u>Methods in Enzymology</u>, R.M. Sweet and C.W. Carter, eds, Academic Press, 277:493-505 (1997)
*		Checa et al., Assessment of Solvation Effects on Calculated Binding Affinity Differences: Trypsin Inhibition by Flavonoids as a Model System for Congeneric Series, <u>J. Med. Chem.</u> 40:4136-4145 (1997).
*		~~Computational Molecular Biology: Sources and Methods for Sequence Analysis~~ Lesk, A.M., ed. Oxford University Press, New York (1988) *noT considered no copy provided*
*		Daniels, Blood group polymorphisms: molecular approach and biological significance, <u>Transfus. Clin. Biol.</u> 4:383-390 (1997).
*		Das et al., Crystal Structures of 8-Cl and 9-Cl Complexed with Wild-type HIV-1 RT and 8-Cl TIBO Complexed with the Tyr181Cys HIV-1 RT Drug-resistant Mutant, <u>J. Mol. Biol.</u> 264:1085-1100 (1996).
*		Devereux et al. A comprhensive set of sequence analysis programs for the VAX, *nucl. Acids Res.* <u>12(1):</u> 387-95 (1984).
*		Dudek et al. Protein Structure Prediction Using a Combination of Sequence Homology and Global Energy Minimization: II. Energy Functions, *Journal Computational Chemistry* <u>19:</u> 548-73 (1998).

EXAMINER	DATE CONSIDERED 11/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan et al.	
	FILING DATE November 10, 2000	GROUP 2857 1631

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

|		
*	JB	Eldridge et al., Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes, Journal of Computer-Aided Molecular Design. 11:425-445 (1997).
*	JB	Erickson et al., Structural Mechanisms of HIV Drug Resistance, Annu. Rev. Pharmacol. Toxicol. 36:545-71 (1996).
*	JB	Fox, S. Pharmacogenomics Thrives in Europe. Genetic Engineering News. June 15, 1999.
*	JB	Goodsell, D.S. and A. J. Olson, Automated Docking of Substrates to Proteins by Simulated Annealing, Proteins: Structure Function, and Genetics 8: 195-202 (1990).
*	JB	Gribskov, M. and R.R. Burgess., Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins, Nucl. Acids Res. 14(1): 6745-63 (1986).
*		~~Guide to Human Genome Computing~~ Bishop, M., ed. Academic Press, Inc., San Diego (1994). not considered no copy provided
*	JB	Gulnik et al. Kinetic Characterization and Cross-Resistance Patterns of HIV-1 Protease Mutants Selected under Drug Pressure, Biochemistry 35: 9282-7 (1995).
*		~~Habuka et al. Crystal Structure of HCV NS3 protease, Jikken Igaku 15(19): 2308-13~~ (1997). not considered no translation or statement of relevance
*	JB	Hess et al., Impact of Pharmacogenomics on the Clinical Laboratory, Molecular Diagnosis 4(4):289-98 (1999).
*	JB	Higgins et al., CABIOS, 8:189-191 (1991)
*	JB	Ingallinella et al., Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products, Biochemistry. 37:8906-8914 (1998).
*	JB	Jacobsen et al. Characterization of Human Immunoeficiency Virus Type 1 Mutanta with Decreased Sensitivity to Protease Inhibitor Ro 31-8959, Virology 206: 527-34 (1995).
*	JB	Kim et al. Crystal Structure of the Hepatitis C virus Ns3 Protease Domain complexed with a Synthetic NS4A Cofactor Peptide, Cell 87: 343-355 (1996).
*	JB	Klabe et al. Resistance to HIV Protease Inhibitors: a Comparison of Enzyme Inhibition and Antiviral Potency, Biochemistry 37: 8735-42 (1998).
*	JB	Kohlstaedt et al. Crystal Structre at 3.5 Angstrom Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor, Science 256: 1783-1790 (1992).

EXAMINER J.B. Brusca	DATE CONSIDERED 11/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan et al.	
	FILING DATE November 10, 2000	GROUP 2857 /63 /

O I P E
MAR 0 5 2001

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*		
*		Kroeger et al. Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains; implications for the mechanism of polymerase action, Protein Engineering 10(12): 1379-1383 (1997).
*		Kuntz et al. Structure-Based Strategies for Drug Design and Discovery, Science 257: 1078-82 (1992).
*		Kuntz et al. A Geometric Approach to Macromolecule-Ligand Interactions, J. Mol. Biol. 161: 269-288 (1982).
*		Lambert, M., Docking Conformationally Flexible Molecules into Protein Binding Sites, in Practical Application of Computer-Aided Drug Design, Charifson, ed. Mercel Dekker, NY, pp.243-303. (1997).
*		Leheny et al. Symposium on Resistance Highlights New Trends in AIDS Treatments: Implications for BioChem Pharma and Others, Hambrecht & Quist LLC Institutional Research. pp. 1-7 (1997). not considered no copy provided
*		Lipman et al., A tool for multiple sequence alignment, Proc. Natl. Acad. Sci. USA 86:4412-5 (1989).
*		Love et al., The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site, Cell. 87:331-342 (1996).
*		Manavalan et al., Location of Potential Binding Sites on Deoxy Hemoglobin for the Design of Antigelling Agents, J. Mol. Biol. 223:791-800 (1992).
*		Maschera et al. Human Immunodeficiency Virus, J. Biol. Chem. 271(52): 33231-5 (1996).
*		Methods in Molecular Biology vol. 24; Computer Analysis of Sequence Data, Part 1. not considered no copy provided Griffin, A. and H.G. Griffin, eds. Humana Press, Inc. Totowa, New Jersey (1994).
*		Momany et al. Energy Parameters in Polypeptides. VII. Geometric Parameters, Partial Atomic Charges, Nonbonded Interactions, Hydrogen Bond Interactions, and Intrinsic Torsional Potentials for the Naturally Occuring Amino Acids, The Journal of Physical Chemistry 79(22): 2361-81 (1975).
*		Munson et al., Identification of an extracytoplasmic region of H +, K(+)- ATPase labeled by a K(+)-competitive photoaffinity inhibitor, J. Biol. Chem. 266(28):18976-88 (1991).
*		Murcko, M.A., An Introduction to De Novo Ligand Design, in Practical Application of Computer-Aided Drug Design, Charifson, ed. Mercel Dekker, NY, pp.305-354. (1997).

EXAMINER	DATE CONSIDERED 11/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan *et al.*	
	FILING DATE November 10, 2000	GROUP ~~2857~~ /b 3/

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*		Nanni *et al.* Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design, *Perspectives in Drug Discovery and Design* 1: 129-50 (1993).
*		Needleman, S.B. and C.D. Wunsch., A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins, *J. Mol. Biol.* 48: 443-53 (1970).
*		Nemethy *et al.* Energy Parameters in Polypeptides. 10. Improved Geometrical Parameters and Nonbonded Interactions for Use in the EEPP/3 Algorithm, with Application to Proline-Containing Peptides, *J. Phys. Chem.* 96: 6472-84 (1992).
*		Nicholls *et al.*, Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons, PROTEINS, Structure, Function and Genetics, 11:281-296 (1991)
*		Novotny *et al.*, Empirical Free Energy Calculations: A Blind Test and Further Improvements to the Method, J. Mol. Biol. 268:401-411 (1997).
*		Ortiz *et al.*, Prediction of Drug Binding Affinities by Comparative Binding Energy Analysis, J. Med. Chem. 38:2681-91 (1995).
*		Pazhanisamy *et al.* Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant Variants, *J. Biol. Chem.* 271(30): 17979-85 (1996).
*		Pearson, W.R. and D.J. Lipman., Improved tools for biological comparison, *Proc. Natl. Acad. Sci. USA* 85: 2444-8 (1988).
*		Ponnuswamy *et al.*, Hydrophobic Packing and Spatial Arrangement of Amino Acid Residues in Globular Proteins, Biochimica et Biophysica Acta 623:301-16 (1980).
*		Ponnuswamy and Prabhakaran, Properties of nucleation sites in globular proteins, Biochem. and Biophys. Res. Comm., 97:1582-1590 (1980)
*		Prabhakaran *et al.*, Sequencing and model strucuture of a *Naja naja atra* protein fragment, J. Peptide Res. 56:12-23 (2000).
*		Press Release, Structural Bioinformatics Inc. Generates Antiviral Lead Compound from Gene Sequence to Achieve Milestone in Biochem Pharma Collaboration, SBI News. Located at http://strubix.com/press/press20.html, pp. 1-2 (1998).
*		Press Release, SBI's Protein Structure Directed Combinatorial Chemistry Cuts Time and Cost 100X for Synthesis of New Anti-Inflammatory Drug Lead Molecules (TNF Receptor Antagonists), SBI News. Located at http://strubix.com/press/press19.html, pp. 1-2 (1998).

EXAMINER	DATE CONSIDERED 11/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan *et al.*	
	FILING DATE November 10, 2000	GROUP ~~2857~~ /63 /

O I P E
MAR 0 5 2001

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*		Press Release, SBI Protein Models & Ligand Binding for Novel Viral Enzyme Validated, <u>SBI News.</u> Located at http://strubix.com/press/press32.html, pp. 1-2 (1999).
*		Press Release, Structural Bioinformatics Inc. Generates Non-Peptide Lead Molecules Active Against the EPO Receptor from Gene Sequence Data, <u>SBI News.</u> Located at http://strubix.com/press/press22.html, pp. 1-2 (1998).
*		Press Release, Structural Bioinformatics Inc. Develops Small-Molecule Antagonists of BCL-2 Gene Product, an Important Apoptosis-Related Protein Target in the Pathology of Human Cancers, <u>SBI News.</u> Located at http://strubix.com/press/press26.html, pp. 1-2 (1999)
*		Press Release, IBM invests in Structural Bioinformatics, a Leading Life Sciences Company; Deal Will Accelerate Drug Discovery Through Faster Modeling of Proteins, Press Release: Nov. 29, 2000, http://www/strubix.com/press/index.html
*		Press Release, Moldyn Technology Enhances the Computational Proteomics Repertoire of SBI to Address the Challenges of 21st Century Molecular Medicine, Press Release: Dec. 5, 2000, http://www/strubix.com/press/index.html
*		Press Release, De Novo Pharmaceuticals Accesses Cutting Edge Protein Targets by Subscription to Structural Bioinformatics' ProMax Database Series and Sbdbase, Press Release: Nov.21, 2000, http://www/strubix.com/press/index.html
*		Press Release, Structural Bioinformatics Inc. and Quest Diagnostics Announce Launch of Structural Pharmacogenomic Databases for HIV Drug Devlopment, Press Release: Jan 11, 2000, http://www/strubix.com/press/index.html
*		Press Release, Structural Bioinformatics' SBdBase 2.0 Provides Improved Functionality for Analyzing Protein Structure to Optimize Drug Candidates, Press Release: Jan. 10, 2000, http://www/strubix.com/press/index.html
*		Press Release, Quest Diagnostics Invests in Structural Bioinformatics, A Leader in Computational Proteomics and Structural Pharmacogenomics, Press Release: Dec. 14, 2000, http://www/strubix.com/press/index.html
*		Press Release, Structural Bioinformatics Inc. Selects IBM RS/6000 SP to Spee Drug Design, <u>SBI News.</u> Located at http://strubix.com/press/press11.html, pp.1-2 (1997).
*		Press Release, Structural Bioinformatics Inc. and Cyberchemics, Inc. Collaborate to Speed the Generation of Hepatitis C Viral Protease Inhibitors, <u>SBI News.</u> Located at http://strubix.com/press/press5.html, pp. 1-2 (1997).
*		~~QSAR and Drug Design: New Developments and Applications T. Fugita, ed. Elsevier~~ Science B.V. (1995) pp.3-81. not considered no copy provided

EXAMINER	DATE CONSIDERED 11/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan *et al.*	
	FILING DATE November 10, 2000	GROUP ~~2857~~ /*b3/*

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| *		
*		Radack *et al.*, Intercorrelations and sources of variability in three mutagenicity assays: a population-based study, <u>Mutation Research.</u> 350 (1996); pp. 295-306.
*		Radmer *et al.*, The application of three approximate free energy calculations methods to structure based ligand design: Trypsin and its complex with inhibitors, <u>Journal of Computer-Aided Molecular Design.</u> 12:215-227 (1998).
*		Ramnarayan *et al.* The effect of polarization energy on the free energy perturbation calculation, *J. Chem. Phys.* <u>92(12):</u> 7057-67 (1990).
*		Ramnarayan *et al.*, Antibody humanization predicted by computer graphic analysis, <u>Am. Biotechnol. Lab.</u> 13(9):26,28 (1995).
*		Ramnarayan *et al.*, Conformational studies on model dipeptides of Gly, L-Ala and their C^α-substituted analogs, <u>Int. J. Pept. Protein Res.</u> 45(4):366-76 (1995).
*		Ramnarayan *et al.*, Characterization of a Linear Pentapeptide Containing Two Consecutive β-Turns, <u>Pept. Res.</u> 7(5):270-8 (1994).
*		Rao *et al.*, Conformational Studies on β-Amino Acid-Containing Peptides. I., <u>Pept. Res.</u> 5(6):343-50 (1992).
*		Regalado, Inventing the pharmacogenomics business, <u>Am. J. Health-Syst. Pharm.</u> 56:40-50 (1999).
*		Richter, R., AIDS drugs found to be effective in world's most common HIV strains January 20, 1999.
*		Salamov and Solovyev, Prediction of protein secondary structure by combining nearest-neighbor algorithms and multiple sequence alignments, <u>J. Mol. Biol.</u> 247:11-15 (1995)
*		Schapira *et al.* Prediction of the binding energy for small molecules, peptides, and proteins, *J. Mol. Recognition* <u>12:</u> 177-90 (1999).
*		Schwartz, R.M. and M.O. Dayhoff., Matrices for Detecting Distant Relationships, Chapter 23 of: Atlas of Protein Sequence and Structure Dayhoff, M.O. ed. National Biomedical Research Foundation pp.353-8 (1978).
*		~~Sequence Analysis Primer Gribskov, M. and J. Devereux (eds.) W.H. Freeman and~~ Company: New York (1992). *not considered no copy provided*
*		~~Sequence Analysis in Molecular Biology: Treasure Trove or Trivial Pursuit von Heijne, G.,~~ ed. Academic Press, Inc. San Diego (1987). *not considered no copy provided*

EXAMINER   *[signature]*   DATE CONSIDERED *11/26/02*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT Ramnarayan *et al.*	
		FILING DATE November 10, 2000	GROUP ~~2857~~ 1631

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*			
*			Shafer *et al.*, Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients, <u>Annals of Internal Medicine.</u> 128(11):906-11 (1998).
*			Shafer *et al.* Human Immunodeficiency Virus reverse Transcriptase and Protease Sequence Database, *Nucl. Acids Res.* <u>27(1):</u> 348-52 (1999).
*			Shafer *et al.* Identification of Biased Amino Acid Substitution Patterns in Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Protease Inhibitors, *Journal of Virology* <u>73(7):</u> 6197-6202 (1999).
*			Shoichet *et al.* Structure-Based Discovery of Inhibitors of Thymidylate Synthase, *Science* <u>259:</u> 1445-50 (1993).
*			Shoichet, B.K. and I.D. Kuntz, Protein Docking and Complementarity, *J. Mol. Biol.* <u>221:</u> 327-46 (1991).
*			Shoichet *et al.*, Ligand Solvation in Molecular Docking, <u>Proteins: Structure, Function, and Genetics.</u> 34:4-16 (1999).
*			Skaletsky *et al.*, Accessing three-dimensional chemical information in antibody molecules, <u>Am. Biotechnol. Lab.</u> 11(5):10-3 (1993).
*			Smith, T. F. and M. S. Waterman., Comparison of Biosequences, *Adv. Appl. Math.* <u>2:</u> 482-489 (1981).
*			Smith *et al.*, Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action, <u>Protein Engineering.</u> 10(12):1379-83 (1997).
*			Spear, Viewpoint - Pharmacogenomics: Today, Tomorrow, and Beyond, <u>Drug Benefit Trends.</u> 11(2):53-54 (1999).
*			Steinkuhler *et al.*, Product Inhibition of the Hepatitis C Virus NS3 Protease, <u>Biochemistry.</u> 37:8899-8905 (1998).
*			Stewart *et al.* Automated 3D Decking: Inhibitors of α-Chymotrypsin, *Medicinal Chemistry Research* <u>1:</u> 439-443 (1992).
*			Takamatsu *et al.*, A New Method for Predicting Binding Free Energy Between Receptor and Ligand, <u>Proteins: Structure, Function, and Genetics.</u> 33:62-73 (1998).
*			Tantillo *et al.* Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse Transcriptase, <u>J. Mol. Biol.</u> 243:369-387 (1994).

EXAMINER	DATE CONSIDERED 11/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24737-1906C	SERIAL NO. 09/709,905
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Ramnarayan et al.	
	FILING DATE November 10, 2000	GROUP 2857 /6 31

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*		Vajda et al. Empirical potentials and functions for protein folding and binding, Theory and Simulation. 7:222-228 (1997).
*		Vriend, G., WHAT IF: A molecular modelling and drug design program, J. Mol. Graphics 8:52-6 (1990).
*		Wang et al., Calculation of Relative Binding Free energies and Configurational Entropies: A Structural and Thermodynamic Analysis of the Nature of Non-polar Binding of Thrombin Inhibitors Based on Hirudin[55-65], J. Mol. Biol. 253:473-492 (1995).
*		Wang et al., Analysis of Thermodynamic Determinants in Helix Propensities of Nonpolar Amino Acids through a Novel Free Energy Calculation, J. Am. Chem. Soc. 118:995-1001 (1996).
*		Wang et al., Toward Designing Drug-Like Libraries: A Novel Computational Approach for Prediction of Drug Feasibility of Compounds, J. Comb. Chem. 1:524-33 (1999).
*		Weiner et al. An All Atom Force Field for Simulations of Proteins and Nucleic Acids, Journal of Computational Chemistry 7(2): 230-52 (1986).
*		Weng et al., Prediction of protein complexes using empirical free energy functions, Protein Science. 5:614-626 (1996). not considered no copy provided
*		Yan et al., Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal form, Protein Science 7:837-847 (1998).
*		Zhou et al. How and why phosphotyrosine-containing peptides bind to the SH2 and PTB domains, Folding & Design. 3(6):513-522 (1998).
*		Zhu et al., Identification of two new hydrophobic residues on basic fibroblast growth factor important for fibroblast growth factor receptor binding, Protein Engineering 11(10):937-40 (1998).
*		Zhu et al., Analysis of high-affinity binding determinants in the receptor binding epitope of basic fibroblast growth factor, Protein Eng. 10(4):417-21 (1997).
*		Zhu et al., Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding. Identification by structure-based site-directed mutagenesis, J. Biol. Chem. 270(37):21869-74 (1995).

EXAMINER J.S. Brusca	DATE CONSIDERED 11/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.